CCIA
BEAM icon

Campbell & Co Investment Adviser’s Beam Therapeutics BEAM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485K Buy
+20,373
New +$565K 0.03% 764
2025
Q4 		– Sell
-16,614
Closed -$403K – 1139
2025
Q3 		$403K Sell
16,614
-210,130
-93% -$4.18M 0.03% 809
2025
Q2 		$3.86M Buy
+226,744
New +$3.95M 0.24% 78

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Campbell & Co Investment Adviser's BEAM Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 20,373 shares worth $485K. The stake represents 0.03% of the portfolio and ranks #764 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in BEAM as recently as Q3 2025.

Campbell & Co Investment Adviser first reported a position in BEAM in Q2 2025 and has held it in 3 quarters since. The position peaked at $3.86M in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Campbell & Co Investment Adviser held 20,373 shares of Beam Therapeutics worth $485K as of Q1 2026.
  • Beam Therapeutics was a new Campbell & Co Investment Adviser position in Q1 2026.
  • Beam Therapeutics made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #764 holding.
  • Campbell & Co Investment Adviser first reported a position in Beam Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Beam Therapeutics position peaked at $3.86M in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.